Recombinant Human IL-33 protein (His Tag)
Species
Human
Purity
>90 %, SDS-PAGE
Tag
His Tag
Activity
not tested
Cat no : Eg0313
Validation Data Gallery
Product Information
| Purity | >90 %, SDS-PAGE |
| Endotoxin | <0.1 EU/μg protein, LAL method |
| Activity |
Not tested |
| Expression | HEK293-derived Human IL-33 protein Ser112-Thr270 (Accession# O95760) with a His tag at the N-terminus. |
| GeneID | 90865 |
| Accession | O95760 |
| PredictedSize | 19.1 kDa |
| SDS-PAGE | 21-26 kDa, reducing (R) conditions |
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization. |
| Reconstitution | Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water. |
| Storage Conditions |
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
|
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature. |
Background
Interleukin-33 (IL-33) is a tissue-derived nuclear cytokine from the IL-1 family abundantly expressed in endothelial cells, epithelial cells and fibroblast-like cells, both during homeostasis and inflammation. IL-33 activates many immune cell types involved in type-2 immunity and allergic inflammation, including ILC2s, mast cells, Th2 cells, eosinophils, basophils, dendritic cells and alternatively activated macrophages (AAM). As a cytokine, IL-33 interacts with the receptors ST2 (also known as IL1RL1) and IL-1 Receptor Accessory Protein (IL1RAP), activating intracellular molecules in the NF-κB and MAP kinase signaling pathways that drive production of type 2 cytokines (e.g. IL-5 and IL-13) from polarized Th2 cells. IL-33 is also effective in reversing Alzheimer-like symptoms in APP/PS1 mice, by reversing the buildup and preventing the new formation of amyloid plaques.
References:
1. Jochen Schmitz. et al. Immunity. (2005) 23(5):479-90. 2. Corinne Cayrol. et al. (2014) Curr Opin Immunol. 31:31-7. 3. Molofsky AB. et al. (2015) Immunity. 2015 Jun 16;42(6):1005-19. 4. Foo YewLiew. et al. (2016)Nat Rev Immunol .16(11):676-689. 5. Amy K Y Fu. et al. (2016) Proc Natl Acad Sci U S A.113(19):E2705-13.